AVE-0118 | CAS#498577-53-0 | Potassium Channel Blocker

MedKoo Cat#: 528004 | Name: AVE-0118

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AVE-0118 is a potassium channel blocker potentially for the treatment of sleep apnea syndrome. AVE0118 effectively suppressed acetylcholine-mediated persistent atrial fibrillation. AVE0118 reduced peak current amplitude of SCN5A-WT current and shifted half-inactivation voltage of the steady-state inactivation curve. AVE0118-induced prolongation of atrial, but not ventricular ERP, is potentially due largely to atrial-selective depression of sodium channel current, which likely contributes to the effectiveness of AVE0118 to suppress atrial fibrillation.

Chemical Structure

AVE-0118

CAS#498577-53-0

Theoretical Analysis

MedKoo Cat#: 528004

Name: AVE-0118

CAS#: 498577-53-0

Chemical Formula: C30H29N3O3

Exact Mass: 479.2209

Molecular Weight: 479.58

Elemental Analysis: C, 75.13; H, 6.10; N, 8.76; O, 10.01

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

AVE-0118; AVE 0118; AVE0118

IUPAC/Chemical Name

2'-((2-(4-methoxyphenyl)acetamido)methyl)-N-(2-(pyridin-3-yl)ethyl)-[1,1'-biphenyl]-2-carboxamide

InChi Key

CHDSRMIDIQABTP-UHFFFAOYSA-N

InChi Code

InChI=1S/C30H29N3O3/c1-36-25-14-12-22(13-15-25)19-29(34)33-21-24-8-2-3-9-26(24)27-10-4-5-11-28(27)30(35)32-18-16-23-7-6-17-31-20-23/h2-15,17,20H,16,18-19,21H2,1H3,(H,32,35)(H,33,34)

SMILES Code

O=C(C1=CC=CC=C1C2=CC=CC=C2CNC(CC3=CC=C(OC)C=C3)=O)NCCC4=CC=CN=C4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 479.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Burashnikov A, Barajas-Martinez H, Hu D, Nof E, Blazek J, Antzelevitch C. Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. J Cardiovasc Pharmacol. 2012 Jun;59(6):539-46. doi: 10.1097/FJC.0b013e31824e1b93. PubMed PMID: 22370957; PubMed Central PMCID: PMC3369013. 2: Wirth KJ, Steinmeyer K, Ruetten H. Sensitization of upper airway mechanoreceptors as a new pharmacologic principle to treat obstructive sleep apnea: investigations with AVE0118 in anesthetized pigs. Sleep. 2013 May 1;36(5):699-708. doi: 10.5665/sleep.2630. PubMed PMID: 23633752; PubMed Central PMCID: PMC3624824. 3: Christ T, Wettwer E, Voigt N, Hála O, Radicke S, Matschke K, Várro A, Dobrev D, Ravens U. Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol. 2008 Aug;154(8):1619-30. doi: 10.1038/bjp.2008.209. PubMed PMID: 18536759; PubMed Central PMCID: PMC2518460. 4: Schneider HJ, Husser O, Rihm M, Fredersdorf S, Birner C, Dhein S, Muders F, Jeron A, Goegelein H, Riegger GA, Luchner A. Safety of the novel atrial-selective K+-channel blocker AVE0118 in experimental heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2009 Mar;379(3):225-32. doi: 10.1007/s00210-008-0361-0. PubMed PMID: 18972103. 5: Oros A, Volders PG, Beekman JD, van der Nagel T, Vos MA. Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block. Heart Rhythm. 2006 Nov;3(11):1339-45. PubMed PMID: 17074641. 6: Billman GE, Kukielka M. Novel transient outward and ultra-rapid delayed rectifier current antagonist, AVE0118, protects against ventricular fibrillation induced by myocardial ischemia. J Cardiovasc Pharmacol. 2008 Apr;51(4):352-8. doi: 10.1097/FJC.0b013e31816586bd. PubMed PMID: 18427277. 7: Kun A, Seprényi G, Varró A, Papp JG, Pataricza J. Neurogenic contraction induced by the antiarrhythmic compound, AVE 0118, in rat small mesenteric arteries. Basic Clin Pharmacol Toxicol. 2014 Oct;115(4):315-20. doi: 10.1111/bcpt.12225. Erratum in: Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):384. PubMed PMID: 24629214. 8: de Haan S, Greiser M, Harks E, Blaauw Y, van Hunnik A, Verheule S, Allessie M, Schotten U. AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation. 2006 Sep 19;114(12):1234-42. PubMed PMID: 16940189. 9: Löfberg L, Jacobson I, Carlsson L. Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. Europace. 2006 Jul;8(7):549-57. PubMed PMID: 16798770. 10: Blaauw Y, Gögelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation. 2004 Sep 28;110(13):1717-24. PubMed PMID: 15364815. 11: Gögelein H, Brendel J, Steinmeyer K, Strübing C, Picard N, Rampe D, Kopp K, Busch AE, Bleich M. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol. 2004 Sep;370(3):183-92. PubMed PMID: 15340774. 12: Wirth KJ, Paehler T, Rosenstein B, Knobloch K, Maier T, Frenzel J, Brendel J, Busch AE, Bleich M. Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs. Cardiovasc Res. 2003 Nov 1;60(2):298-306. PubMed PMID: 14613859. 13: Schotten U, de Haan S, Verheule S, Harks EG, Frechen D, Bodewig E, Greiser M, Ram R, Maessen J, Kelm M, Allessie M, Van Wagoner DR. Blockade of atrial-specific K+-currents increases atrial but not ventricular contractility by enhancing reverse mode Na+/Ca2+-exchange. Cardiovasc Res. 2007 Jan 1;73(1):37-47. PubMed PMID: 17157284. 14: Blaauw Y, Schotten U, van Hunnik A, Neuberger HR, Allessie MA. Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat. Cardiovasc Res. 2007 Jul 1;75(1):89-98. Erratum in: Cardiovasc Res. 2007 Nov 1;76(2):373. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. PubMed PMID: 17466958. 15: Decher N, Kumar P, Gonzalez T, Pirard B, Sanguinetti MC. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation. Mol Pharmacol. 2006 Oct;70(4):1204-11. PubMed PMID: 16835355. 16: Tikhonov DB, Zhorov BS. Homology modeling of Kv1.5 channel block by cationic and electroneutral ligands. Biochim Biophys Acta. 2014 Mar;1838(3):978-87. doi: 10.1016/j.bbamem.2013.11.019. PubMed PMID: 24316168. 17: Linz DK, Afkham F, Itter G, Rütten H, Wirth KJ. Effect of atrial electrical remodeling on the efficacy of antiarrhythmic drugs: comparison of amiodarone with I(Kr)- and I(to)/IKur-blockade in vivo. J Cardiovasc Electrophysiol. 2007 Dec;18(12):1313-20. PubMed PMID: 17916155. 18: van Hunnik A, Lau DH, Zeemering S, Kuiper M, Verheule S, Schotten U. Antiarrhythmic effect of vernakalant in electrically remodeled goat atria is caused by slowing of conduction and prolongation of postrepolarization refractoriness. Heart Rhythm. 2016 Apr;13(4):964-72. doi: 10.1016/j.hrthm.2015.12.009. PubMed PMID: 26681610. 19: Hernández GP, Ortíz PL, López FA, Mondragón Ldel V. [New antiarrhythmic agents in atrial fibrillation]. Arch Cardiol Mex. 2007 Apr-Jun;77 Suppl 2:S2-59-S2-63. Review. Spanish. PubMed PMID: 17972381. 20: Linz D, Schotten U, Neuberger HR, Böhm M, Wirth K. Combined blockade of early and late activated atrial potassium currents suppresses atrial fibrillation in a pig model of obstructive apnea. Heart Rhythm. 2011 Dec;8(12):1933-9. doi: 10.1016/j.hrthm.2011.07.018. PubMed PMID: 21767520.